Revisiting the role of MicroRNAs in the pathogenesis of idiopathic pulmonary fibrosis
Authors:
Open Access
- 16 October 2024
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 12, 1470875
Abstract
Idiopathic pulmonary fibrosis (IPF) is a prevalent chronic pulmonary fibrosis disease characterized by alveolar epithelial cell damage, fibroblast proliferation and activation, excessive extracellular matrix deposition, and abnormal epithelial-mesenchymal transition (EMT), resulting in tissue remodeling and irreversible structural distortion. The mortality rate of IPF is very high, with a median survival time of 2–3 years after diagnosis. The exact cause of IPF remains unknown, but increasing evidence supports the central role of epigenetic changes, particularly microRNA (miRNA), in IPF. Approximately 10% of miRNAs in IPF lung tissue exhibit differential expression compared to normal lung tissue. Diverse miRNA phenotypes exert either a pro-fibrotic or anti-fibrotic influence on the progression of IPF. In the context of IPF, epigenetic factors such as DNA methylation and long non-coding RNAs (lncRNAs) regulate differentially expressed miRNAs, which in turn modulate various signaling pathways implicated in this process, including transforming growth factor-β1 (TGF-β1)/Smad, mitogen-activated protein kinase (MAPK), and phosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT) pathways. Therefore, this review presents the epidemiology of IPF, discusses the multifaceted regulatory roles of miRNAs in IPF, and explores the impact of miRNAs on IPF through various pathways, particularly the TGF-β1/Smad pathway and its constituent structures. Consequently, we investigate the potential for targeting miRNAs as a treatment for IPF, thereby contributing to advancements in IPF research.Keywords
This publication has 232 references indexed in Scilit:
- miRNA‐34c‐5p targets Fra‐1 to inhibit pulmonary fibrosis induced by silica through p53 and PTEN/PI3K/Akt signaling pathwayEnvironmental Toxicology, 2022
- Human bronchial epithelial cell‐derived extracellular vesicle therapy for pulmonary fibrosis via inhibition of TGF‐β‐WNT crosstalkJournal of Extracellular Vesicles, 2021
- Mesenchymal stem cell‐derived extracellular vesicles suppress the fibroblast proliferation by downregulating FZD6 expression in fibroblasts via micrRNA‐29b‐3p in idiopathic pulmonary fibrosisJournal of Cellular Physiology, 2020
- MicroRNA‐448 overexpression inhibits fibroblast proliferation and collagen synthesis and promotes cell apoptosis via targeting ABCC3 through the JNK signaling pathwayJournal of Cellular Physiology, 2019
- MiR‐448‐5p inhibits TGF‐β1‐induced epithelial‐mesenchymal transition and pulmonary fibrosis by targeting Six1 in asthmaJournal of Cellular Physiology, 2018
- Downregulation of microRNA‐9 reduces inflammatory response and fibroblast proliferation in mice with idiopathic pulmonary fibrosis through the ANO1‐mediated TGF‐β–Smad3 pathwayJournal of Cellular Physiology, 2018
- A novel molecular mechanism of microRNA‐21 inducing pulmonary fibrosis and human pulmonary fibroblast extracellular matrix through transforming growth factor β1–mediated SMADs activationJournal of Cellular Biochemistry, 2018
- Mesenchymal stromal cells prevent bleomycin‐induced lung and skin fibrosis in aged mice and restore wound healingJournal of Cellular Physiology, 2017
- Impact of cell culture parameters on production and vascularization bioactivity of mesenchymal stem cell‐derived extracellular vesiclesBioengineering & Translational Medicine, 2017
- miR‐19a, ‐19b, and ‐26b Mediate CTGF Expression and Pulmonary Fibroblast DifferentiationJournal of Cellular Physiology, 2016